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Abstract
Background: Inhabitants of Appalachian Kentucky are encumbered by tremendous health
disparities, exhibit high rates of prescription drug abuse, and often co-present with psychiatric
disorders. Compared to opioids, little research has focused on the nonmedical use of
benzodiazepines.
Objective: To examine the association between nonmedical benzodiazepine use and major
depressive disorder (MDD), generalized anxiety disorder (GAD), post-traumatic stress disorder
(PTSD), and anti-social personality disorder (ASPD) in a population of opioid drug abusers.
Methods: Data for this cross-sectional study was obtained from the Social Networks among
Appalachian People (SNAP) study. Contingency tables analysis and the X2statistic were used to
examine the association between past 30 day benzodiazepine (i.e., alprazolam, clonazepam,
diazepam) use and psychiatric diagnoses. The independent correlates of recent benzodiazepine
use were determined using multiple logistic regression.
Results: 503 participants were included in this analysis. All reported a lifetime history of opioid
drug abuse and 98% (n=493) reported use within the past 30 days. 71% (n=355) reported past
30 day benzodiazepine (i.e., alprazolam, clonazepam, or diazepam) use. The presence of MDD
(Odds Ratio [OR]: 1.9, 95% Confidence Interval [CI]: 1.2-3.0) or GAD (OR: 1.9, 95% CI: 1.23.0) were significantly (p<0.05) associated with recent benzodiazepine use. Other variables
associated with benzodiazepine use were: illicit methadone use (Adjusted OR [AOR]: 2.94, 95%
CI: 1.9-4.56, marijuana use(AOR: 2.57, 95% CI: 1.64-4.01), oxycodone use (AOR: 2.52, 95%
CI: 1.6-3.97), GAD (AOR: 1.67, 95% CI: 1.01-2.77), poor/fair health (AOR: 1.65, 2.6), and
years living in eastern Kentucky (AOR: 1.03, 95% CI: 1.0-1.1).
Discussion: The results show a strong association between nonmedical benzodiazepine use and
psychiatric disorders (i.e., MDD, GAD). A lack of accessible mental healthcare providers may
be a contributing factor to the high rates of nonmedical benzodiazepine use found in this study.
Longitudinal studies are needed to examine the effect of prescription drug monitoring programs
on benzodiazepine abuse.
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1. Introduction
Prescription drugs are the second most abused class of drugs in the United States.

The

prevalence of prescription drug abuse has rapidly increased over the past decade with one in
every five Americans over the age of 12 now being able to report using a prescription drug for a
nonmedical purpose at least once in their lifetime.1 This epidemic has taken a toll not only on
individual abusers, but the entire country. Prescription opioids are the most common class of
medications abused with their total yearly economic cost of nonmedical use being more than $50
billion.2 Accordingly, the majority of prescription drug abuse research has been focused on
opioids. However, other prescription medications, such as benzodiazepines, are also frequently
abused.
Benzodiazepines are Schedule IV medications and exert their pharmacologic effects by binding
to receptors in the brain, which in turn increase the effects of gamma-aminobutyric acid
(GABA). GABA is an inhibitory neurotransmitter that produces a calming and sedating effect.
Benzodiazepines are approved for the short term treatment of anxiety but are also frequently
prescribed long term and for uses other than their labeled indications.
Between 1998 and 2007, the number of alprazolam and clonazepam prescriptions dispensed
through outpatient retail pharmacies increased 71% and 114% respectively.3 One substantial
issue in relation to prescription drug abuse is the treatment of patients with chronic pain. A
common “drug cocktail” prescribed to patients with chronic pain consists of an opioid,
benzodiazepine, and muscle relaxer. This combination of drugs is frequently prescribed to
patients suffering from chronic pain despite a lack of proven clinical benefit. The prevalence of
benzodiazepine prescribing has been increasing at a rate comparable to that of opioids4, but
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research investigating the factors associated with abuse and nonmedical use of benzodiazepines
is lacking.
Residents of the Appalachian region of Kentucky suffer from severe health disparities and have
rates of prescription drug abuse and mental health disorders that exceed national averages.5 The
self-medication hypothesis of addictive disorders, first described by Dr. Edward Khantzian, may
explain this relationship.6 This hypothesis suggests that individuals with psychiatric disorders
crave certain drugs of abuse because of the specific pharmacologic properties of the drug. Thus,
the primary objective of this study was to determine if a relationship exists between nonmedical
benzodiazepine use and DMS-IV psychiatric disorders such as: major depressive disorder
(MDD), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) in a
population of opioid drug abusers residing in Appalachian Kentucky. The hypothesis being that
drug abusers with an underlying psychiatric illness may use benzodiazepines to self-medicate
comorbid conditions. A secondary objective of this study was to identify the demographics
associated with the nonmedical use of benzodiazepines, specifically alprazolam, clonazepam,
and diazepam.

The study also examined the correlation of other drugs of abuse with the

nonmedical use of benzodiazepines. The final objective of this study is to categorize the sources
from which users obtained their first time supply of a benzodiazepine for a nonmedical purpose.
2. Methods
This retrospective cross-sectional study analyzes data acquired from the Social Networks among
Appalachian People (SNAP) study. SNAP is an ongoing longitudinal cohort study of social
networks and HIV risk among rural Appalachian drug users who reside in Perry County,
Kentucky. Perry County has a population of approximately 30,000 and is located in Southeastern
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Kentucky. The vast majority of the population is white (97%), with an average yearly household
income of $33,000, and with 26% of individuals living in poverty.7 The SNAP study was
approved by the Institutional Review Board (IRB) at the University of Kentucky.
SNAP study participants were recruited using Respondent Driven Sampling (RDS) which has
been effectively utilized in previous studies of hard to reach populations such as rural drug
users.8 Initial recruits were identified via community outreach, word-of-mouth, and flyers.
These initial recruits then solicited peers to participate in the study. Subjects were monetarily
reimbursed for successfully recruiting additional eligible study participants.

This process

continued until the desired sample size was attained (n=503).
Trained non-clinician researchers conducted baseline interviews and used the Addiction Severity
Index (ASI)9 to determine illicit and prescription drug use. Psychiatric disorders were diagnosed
using the Mini-International Neuropsychiatric Interview (MINI), version 5.0.10 Demographic
variables collected through completion of the ASI included age, gender, years of education,
employment, financial status, health insurance status, health status, and a detailed history of both
lifetime and past 30 day nonmedical substance use.

The MINI was used to evaluate if

Diagnostic and Statistical Manual of Mental Disorders criteria were met for current major
depressive disorder (MDD), generalized anxiety disorder (GAD), post-traumatic stress disorder
(PTSD), and/or antisocial personality disorder (ASPD).

Additionally, participants were

questioned regarding specific nonmedical drug sources (i.e., family member, friend, dealer).
Participants were asked to provide specific drug names or street names in order to record lifetime
and past 30 day use of substances for a nonmedical purpose (e.g., “to get high”). The correct
categorization of substances reported was confirmed before data analysis. For the purposes of
data analysis, only subjects that were categorized as using alprazolam, clonazepam, or diazepam
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within the past 30 days were labeled as benzodiazepine users. All data capable of identifying
individual participants was purged before analysis.

The Institutional Review Board at the

University of Kentucky granted an IRB exemption for this study.
Subjects were divided into two groups, “past 30 day users of benzodiazepines” and “past 30 day
non-users”, and the descriptive statistics were reported via a univariate analysis. The Chi-square
test, Fisher’s Exact test, and the Mann-Whitney rank-sum test for categorical and continuous
variables were utilized to compare the demographic and substance abuse characteristics of each
group respectively. The chi-square test was utilized to identify significant (p<0.05) differences
in the prevalence of MDD, GAD, PTSD, and ASPD between recent benzodiazepine users and
non-users. Finally, independent correlates of past 30 day benzodiazepine use were determined
using a step-wise multiple logistic regression with an adjusted odds ratio (AOR) and 95%
confidence intervals (CI) reported for each variable. SPSS, version 20, was utilized for all
analyses.
3. Results
503 participants were included in the study analysis. The majority of participants were male
(57%, n=206), white (94%, n=473), and had at least a high school education (56%, n=284). The
median age of participants was 33 years (interquartile range: 26 to 38 years). All participants
reported a history of nonmedical prescription opioid use, and 98% (n=493) reported past 30 day
use.
Table 1 displays the baseline characteristics among those who did (n=355) and did not (n=148)
report any past 30 day use of alprazolam, clonazepam, or diazepam. Median and interquartile
range (IQR) of age and years of education completed did not significantly differ (p=0.2, p=0.8,
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respectively) between those who had used benzodiazepines and those who had not. However,
benzodiazepine users did report a significantly greater (p=0.02) median of years of residence in
Eastern Kentucky (n=30 years), than those who did not (n=27 years). Benzodiazepine users
were significantly more likely to describe themselves as religious (p=0.01) and non-white
(p=0.02) as compared to non-users. No significant differences in the socio-economic status were
found among benzodiazepine users and non-users. However, subjects who reported their selfperceived health status as poor or fair had a 12.4% higher prevalence of benzodiazepine use
(p=0.01). Contrary to the results of perceived health status, the presence of chronic health
conditions was not significantly different among benzodiazepine users and non-users (p=0.1).
Additionally, there was no significant difference in the type of health insurance (i.e.., Medicaid,
Medicare, private) used in terms of benzodiazepine users and non-users.
Table 2 displays the univariate comparison of past 30 day substance use among benzodiazepine
users and non-users. The benzodiazepine group reported significantly higher rates of past 30 day
use of several substances when compared to non-users. Participants who reported past 30 day
use of benzodiazepines were also 24% more likely to have illicitly used methadone (p<0.001),
23.1% more likely to use oxycodone (p<0.001), 18.8% more likely to use marijuana (p<0.001),
and 12.7% more likely to use alcohol (p=0.01).

The prevalence of reported past 30 day

benzodiazepine use was very high with 71% (n=355) of participants reporting having used one
or more benzodiazepines (i.e., alprazolam, clonazepam, or diazepam) at least once during the
previous 30 day period. 88.5% (n=314) of participants who reported using benzodiazepines
within the past 30 days reported using alprazolam. Clonazepam was the second most commonly
used benzodiazepine with 190 subjects (54%) reporting using the prescription drug for
nonmedical purposes. Diazepam, with 115 (32%) subjects reporting its use, was the least
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commonly utilized benzodiazepine evaluated in this study. The majority of subjects reported
using alprazolam only (n=119, 33.5%). 25.4% (n=90) subjects reported using both alprazolam
and clonazepam, and 65 subjects (18.3%) reported using all three benzodiazepines (i.e.,
alprazolam, clonazepam, diazepam) evaluated in this study (Table 3). As shown in Table 4, the
most common primary source of benzodiazepines was from friends or family members (n=211,
59%). The next most common source was from a dealer (n=60, 17%). Only 15% (n=53) of
benzodiazepine users obtained their first prescription legitimately via a clinician such as a
physician or dentist.
A strong relationship between the nonmedical use of benzodiazepines and DSM-IV psychiatric
disorders was found in this study (Table 5). Participants that reported past 30 day use of
alprazolam, clonazepam, and/or diazepam were found to have an 11.1% (p=0.01) higher
prevalence of MDD versus benzodiazepine non-users. Additionally, the prevalence of GAD was
12.4% higher (p=0.005) in subjects who reported past 30 day benzodiazepine use. Although
6.6% more participants who reported recent benzodiazepine use met the criteria for a PTSD
diagnosis, the relationship did not achieve statistical significance (p=0.053). Finally, the rates of
ASPD were nearly identical between benzodiazepine users and non-users, 31.5% versus 31.1%
respectively (p=0.9).
A logistic regression model (Table 6) was developed to identify independent correlates of recent
benzodiazepine use. After controlling for the possible confounding variables of age, sex, and
race, the adjusted model revealed six variables associated with past 30 day benzodiazepine use.
The strongest association was with illicit methadone use (AOR: 2.9, 95% CI: 1.9-4.6). Other
benzodiazepine abuse factors included marijuana use (AOR: 2.6, 95% CI: 1.6-4.01) and
oxycodone use (AOR: 2.5, 95% CI: 1.6-3.97).

During the modeling process, substantial
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collinearity between GAD and MDD was identified. Although both disorders were associated
with benzodiazepine use, a diagnosis of GAD via the MINI was the more significant factor of
benzodiazepine use (AOR: 1.7, 95% CI: 1.01-2.77) in the final model. A self-reported health
status of poor or fair (AOR: 1.65, 95% CI: 1.05-2.6) as well as number of years a subject
reported living in Appalachian, Kentucky (AOR: 1.03, 95% CI: 1.0-1.05) were also significant
contributors to recent benzodiazepine use in the adjusted logistic model.
4. Discussion
The findings of this study are consistent with the hypothesis that nonmedical benzodiazepine use
is strongly associated with major depressive disorder (MDD) and generalized anxiety disorder
(GAD).

While other reports have described the common co-occurrence of psychiatric and

substance use disorders11; this is the first study to suggest that people who abuse benzodiazepines
are significantly more likely to have specific psychiatric disorders.

Therefore, future treatment

and prevention programs must be developed to target both addiction and underlying psychiatric
disorders.

Overall, 26% of participants were found to have MDD without regard to

benzodiazepine use. This rate is in agreement with recent literature that places the lifetime rate
of developing a concurrent substance use disorder and MDD at 17.2%.12 The results of this
study raise the question of potential self-medication among opioid drug abusers. We found that
those who met DSM-IV criteria for MDD or GAD were almost twice more likely to report
nonmedical benzodiazepine use than those who did not. Considering benzodiazepines are
indicated for the short term treatment of anxiety, benzodiazepine use was likely providing relief
to an anxiety prone population of opioid drug abusers. This study did not find a significant
relationship between benzodiazepine use and PTSD. While this result was plausibly due to the
relatively small prevalence of PTSD among the study population; this finding was unexpected
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due to a commonly held assumption regarding substance abuse as a coping mechanism utilized
by individuals with PTSD.13
It is expected that the high prevalence of psychiatric conditions in this study contributed to
subjects self-perceived health status. This study found poor health status was significantly
associated with nonmedical use of benzodiazepines. However, whether poor health was a factor
promoting benzodiazepine use or if benzodiazepine use led to decreased health cannot be
determined. Of note, previous studies have found opioid users who co-abuse benzodiazepines
experience higher substance dependence relapse rates and in general, poorer treatment
outcomes.14,15 Therefore, an investment in overcoming health disparities may be needed to stem
the epidemic of drug abuse.
The large percentage of benzodiazepine users in this study is in accordance with existing
literature which suggests that opioids and benzodiazepines are commonly abused in tandem for
nonmedical purposes. Several studies have evaluated the drug use history of patients entering
methadone clinics for treatment of opioid dependence. These studies found that anywhere
between 18-54% of admitted patients required detoxification from benzodiazepines.16,17,18
Alprazolam, which is the most commonly prescribed benzodiazepine nationally19, was also the
most prevalent benzodiazepine reportedly used in this study of opioid drug users.
The high prevalence of opioid and benzodiazepine co-use is concerning for several reasons.
First, current practice guidelines do not support the long term use of benzodiazepines to treat
anxiety. Also, benzodiazepines have been shown to be of little benefit for patients suffering
from chronic pain.20 Compounding these dangers, is the fact that many benzodiazepines increase
opioid associated respiratory depression. Additionally, the effectiveness of the opioid antagonist
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naloxone is decreased in the presence of benzodiazepines thus potentially hampering the
treatment of acute overdoses. Statistics regarding acute overdose were not collected in this
study, but opioids and benzodiazepines are reportedly the most common prescription drugs
involved in these types of clinical scernarios.21
Benzodiazepines have been shown to increase the rewarding and reinforcing effects of opioids
which potentiates further abuse and dependence.22 Of note is the strong association between
nonmedical use of benzodiazepines and illicit methadone and oxycodone use found in this study.
This finding is consistent with literature that found drug users will augment the effects of
oxycodone with benzodiazepines to increase their “high.”23 This observation is supported by
pharmacokinetic studies that found that diazepam increased the concentration of methadone in
the central nervous system.24 Interestingly, this association was not noted in subjects reporting
the use of Oxycontin®.

Since Oxycontin® is a potent long acting formulation of oxycodone,

this suggests opioid abusers may be utilizing benzodiazepines to intensify the effects of less
potent narcotics.
Residents of Appalachia are often self-sufficient and distrustful of the healthcare system.25,26
These traits give credence to the hypothesis of practicing self-medication to treat psychiatric
disorders. This study found that the odds of using a benzodiazepine increase by 3% each
additional year living in Eastern Kentucky, which suggests that as immersion in Appalachian
culture increases, the likelihood of seeking professional treatment decreases. It is possible many
participants were hesitant to seek professional assistance because of the stigma associated with
psychiatric disorders. This study found that more than half of recent benzodiazepine users
obtained their supply from friends or family members. These findings are consistent with a 2012
national study by McCabe et al. which reported that 55% of teenage subjects reporting
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nonmedical use of opioids acquired them from friends or family.27 Since the diversion of
prescription pharmaceuticals is a contributing factor in over half of all fatal drug overdoses28, an
investment in campaigns that educate the public regarding the dangers of sharing prescription
drugs appears to be warranted especially in this rural population.
The main limitation of this study is its cross-sectional design which does not allow for causality
to be established.

A further limitation of this study is that no measure of degree of

benzodiazepine abuse or dependence was collected. Due to the constraint of using secondary
data, only participants reporting the use of alprazolam, clonazepam, or diazepam were classified
as benzodiazepine users. Therefore, it is possible a subject may have been mistakenly classified
as a benzodiazepine non-user when in fact they used another agent of the class. However, since
most participants reported using more than one benzodiazepine, this limitation likely had little
impact on final results. Lastly, since the study population consisted of rural opioid users living
in only one county of Kentucky, the results of this study may not be generalizable to all opioid
users.
Despite these limitations, this study suggests nonmedical benzodiazepine use is associated with
psychiatric disorders and reinforces the fact that nonmedical use of prescription drugs is a multifaceted problem. The results of this study reinforce the need for intervention at both the
individual and community level. High rates of MDD and GAD were found among this cohort of
opioid drug abusers living in medically underserved region of Appalachian, Kentucky. The
association of MDD and GAD with benzodiazepine use suggests subjects were possibly selftreating their conditions by escalating their degree of prescription drug abuse to include
benzodiazepines. A lack of accessible mental healthcare providers may be a contributing factor
to the high rates of nonmedical benzodiazepine use found in this study.

An additional
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contributing factor may be that people suffering from mood disorders fear exclusion in these
typically clannish communities.

If this is the case, further development of mental health

outreach programs and access to healthcare services may reduce the abuse of benzodiazepines in
Appalachian Kentucky.

In 2012, the Kentucky legislature passed House Bill 1 in an attempt to

improve prescription oversight of controlled substances. This legislation imposes regulations
concerning pain clinics, improved guidelines for the prescribing of controlled substances, and
requires the mandatory utilization of an electronic prescription drug monitoring program (e.g,
KASPER [Kentucky All Schedule Prescription Electronic Reporting]). Longitudinal studies are
needed to determine the effect of prescription drug monitoring programs (e.g., KASPER) on the
accessibility of benzodiazepines. By limiting accessibility of these drugs, users may seek out the
psychiatric treatment they require instead of attempting to self-medicate by using
benzodiazepines and other drugs of abuse.

However, due to the strong association of

prescription drug abuse and psychiatric disorders, the provision of mental healthcare must be of
utmost importance in order to stem the tide of drug abuse in Appalachian Kentucky.
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Table 1. Demographic data

Demographics

Median age (IQR)
Median years lived in
Eastern Kentucky
(IQR)
Median years of
education completed
(IQR)
Male gender
Religious
Caucasian
Employment
Full-time
Part-time
Disabled
Student/service/military
Controlled
environment
Unemployed
Pension for physical
disability
Someone contributes
majority of support
Health insurance status
Medicaid/Medicare
Private
Uninsured
Self-reported health
status
Poor/fair
Good
Very good/excellent
Chronic health
condition(s)
Ever treated for drug
abuse

Benzo Use
30 d
(n=355)

No Benzo Use
30 d
(n=148)

Total
(n=503)

n
%
33 (26-38)

n
%
32 (25-36)

P
0.153

n
%
33 (26-38)

29 (24-35)

27 (22-33)

0.015

28 (23-25)

11 (10-12)

11 (10-12)

0.841

11(10-12)

194
112
329

54.6
31.5
92.7

92
29
145

62.2
19.6
98.0

0.121
0.007
0.020

286
141
474

56.9
28.0
94.2

114
90
48
6

32.1
25.4
13.5
1.7

59
26
19
2

39.9
17.5
12.8
1.4

0.095
0.059
0.837
1.00

173
116
67
8

34.4
23.1
13.3
1.6

2

1.4

6

1.7

.0096

8

1.6

95

26.8

36

24.3

0.57

131

26.0

41

11.5

20

13.5

0.539

61

12.1

143

40.3

47

31.8

0.072

190

37.8

108
14
233

30.4
3.9
65.6

44
4
100

29.7
2.7
67.6

0.877
0.606
0.676

152
18
333

30.2
3.6
66.2

178
126
51

50.2
35.5
14.3

56
67
25

37.8
45.3
16.9

0.012
0.051
0.471

234
193
76

46.5
38.4
15.1

131

36.9

44

29.7

0.124

175

34.8

177

49.9

79

53.4

0.472

256

50.9
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Table 2. Prevalence of psychiatric disorders and substance abuse
Psychiatric
disorders

MDD
GAD
PTSD
ASPD
Substance use
(30 day)
Any opioid
Alcohol
Heroin
Illicit methadone
Licit methadone
Oxycodone ER
Oxycodone
Crack
Cocaine
Methamphetamine
Marijuana

Benzo Use
30 d
(n=355)
n
%
104
29.3
116
32.7

No Benzo Use
30 d
(n=148)
n
%
27
18.2
30
20.3

Total
(n=503)
P
0.01
0.005

n
131
146

%
26.0
29.0

57
112

16.1
31.5

14
46

9.5
31.1

0.053
0.918

71
158

14.1
31.4

352
208
14
241
12
252
281
45
88
14
237

99.2
58.6
3.9
67.9
3.4
71.0
79.2
12.7
24.8
3.9
66.8

141
68
8
65
2
99
83
12
25
3
71

95.3
45.9
5.4
43.9
1.4
66.9
56.1
8.1
16.9
2.0
48

0.009
0.009
0.465
0.000
0.207
0.362
0.000
0.141
0.053
0.278
0.000

493
276
22
306
14
351
364
57
113
17
285

98.0
54.9
4.4
60.8
2.8
69.8
72.4
11.3
22.5
3.4
56.7
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Table 3. Detailed analysis of benzodiazepine use (n=355)
Self-reported benzodiazepine use
Alprazolam alone
Clonazepam and alprazolam
Alprazolam, clonazepam,
diazepam
Diazepam and alprazolam
Clonazepam alone
Diazepam alone
Clonazepam and diazepam
Total

n
119
90
65

%
33.5
25.4
18.3

40
31
6
4
355

11.3
8.7
1.7
1.1
100
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Table 4. Sources of benzodiazepines
Source first time used benzodiazepine
n
%
16
4.5
Spouse
57
16.1
Family
138
38.9
Friends
14.6
Physician/Dentist 52
60
16.9
Dealer
17
4.8
Stolen
1
0.3
Multiple sources
14
3.9
No response
355
100
Total
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Table 5. Association between benzodiazepine use and psychiatric disorders
Association between benzodiazepine use and psychiatric disorders
MDD
GAD
Odds
Odds
95% CI
P
95% CI
P
Ratio
Ratio
0.7910.550Alprazolam
1.250
0.338 0.871
0.557
1.974
1.381
alone
0.1980228Clonazepam
0.528
0.194 0.569
0.221
1.405
1.418
alone
1.050.056Diazepam
5.827
0.042 0.486
0.677
32.194
4.192
alone
Clonazepam
0.8960.0848.695
0.056 0.814
1.000
and
84.340
7.888
diazepam
Clonazepam
0.7180.9511.192
0.497 1.537
0.078
and
1.978
2.484
alprazolam
Diazepam
0.4470.6840.942
0.875 1.350
0.386
and
1.985
2.666
alprazolam
Alprazolam,
0.8110.218
1.2972.210
0.003
clonazepam, 1.423
2.499
3.766
diazepam
1.1541.208Total
1.857
0.010 1.909
0.005
2.988
3.018

Odds
Ratio
0.845
0.403
1.220

PTSD
95%
CI
0.4591.556
0.0941.727
0.14010.598

P
0.588
0.289
0.601

2.043

0.21019.917

0.457

1.151

0.6102.171

0.665

2.548

1.2095.367

0.011

1.638

0.8403.193

0.144

1.831

0.9863.400

0.053
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Table 6. Independent factors of past 30 day benzodiazepine use
Factors of benzodiazepine use in opioid drug abusers
Odds Ratio
Adjusted Odds Ratio*
2.755
2.944
Illicit methadone
2.264
2.565
Marijuana
2.463
2.521
Oxycodone
1.736
1.669
GAD
1.751
1.652
Poor/Fair health
Time lived in eastern
1.027
1.028
KY
*controlling for age, sex, race

95% CI
1.902-4.557
1.640-4.013
1.602-3.968
1.005-2.770
1.049-2.600
1.004-1.052
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Figure 1. Self-reported benzodiazepine use

Self-reported past 30 day benzodiazepine use
Alprazolam alone

9%

2%

11%
18%

1%

34%
25%

Clonazepam &
alprazolam

Alprazolam,
clonazepam, &
diazepam
Diazepam &
alprazolam
Clonazepam alone

Diazepam alone
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Figure 2. Association of benzodiazepine use with psychiatric disorders
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Figure 3. Forest plot of factors of benzodiazepine use
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Figure 4. Sources of benzodiazepines

Sources of Benzodiazepines
0.30%
4.80%

3.90% 4.50%
Spouse

16.90%

16.10%

Family
Friends
Physician/Dentist

14.60%
38.90%

Dealer
Stolen
Multiple sources
No response

